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Abstract
A 61-year-old woman who underwent HeartMate II left ventricular assist device
placement for non-ischemic cardiomyopathy developed elevated lactate
dehydrogenase within two weeks after implantation. After eight months of
observation and several hospital admissions during which there was no
evidence of pump thrombosis, she presented with clinically manifest
hemolysis. During pump exchange there was notable pannus formation on the
inflow cannula of the left ventricular assist device. The pannus around the
inflow likely existed for several months, limiting the flow and creating a lowgrade hemolysis and this low flow state stimulated thrombus formation
triggering gross hemolysis. Thoratec analysis of the pump confirmed that the
clot was present for about 5 days. Lactate dehydrogenase normalized after
pump exchange.
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Introduction
Left ventricular assist devices (LVAD) have become an integral tool in the
treatment of patients with refractory heart failure [1] as they decrease morbidity,
prolong survival [2] and improve the quality of life [3]. According to the
INTERMACS registry, more than 10000 LVADs have been implanted since 2006
in yearly increasing increments with nearly 2500 LVADs implanted in 2013 [4].
Recently, several high volume LVAD centers reported markedly increased
incidence of pump thrombosis compared with the data from clinical trials [5]. This
complication typically presents as hemolysis, and elevated lactate
dehydrogenase (LDH) is the most reliable early sign [6]. Therefore, many centers
routinely follow LDH level after LVAD implantation and advise immediate
hospitalization based on elevated LDH alone. Other causes of LVAD obstruction,
resulting in elevated LDH, are less frequent. There is scant data in the literature
on hemolysis due to pannus formation. We describe a case of consistently
elevated LDH for 8 months after LVAD implant due to pannus formation causing
partial obstruction of the inflow cannula followed by gross hemolysis with onset of
pump thrombosis.

Case presentation
A 61 year-old-woman with non-ischemic cardiomyopathy had recurrent hospital
admissions due to decompensated heart failure and underwent HeartMate II
LVAD placement. Preoperative laboratory workup showed no features of
hypercoagulability. Heparin infusion was initiated on postoperative day 1 with a
target partial thromboplastin time of 55- 65 seconds until an INR level of 2 was
achieved. She was discharged on aspirin, persantine, and warfarin therapy. Her
baseline LDH ranged between 400 and 500 IU/L. Within the first two weeks after
LVAD implantation LDH started rising, never decreased to a level below 600
IU/L, ranging between 652 to 2258 IU/L. Because of this, the goal for INR was
increased to 2.5-3.5, and she stayed within the range. Although she felt
somewhat better than before surgery, walking longer and further caused
lightheadedness, and over the course of several months she had two falls. Her
target INR was increased to 2.5-3.5. Two months after this adjustment, she was
admitted with gastrointestinal bleeding, and her INR goal was shifted again to
2.0-3.0. In addition we lowered the dose of aspirin from 325 mg/day to 81 mg/day
and discontinued persantine.
An echocardiogram showed 2D and color Doppler features consistent with
normal appearance of the LVAD device. On ramp study, with the device speed
changed from 8000 rpms to 11000 rpms, left ventricular end-diastolic dimension
decreased from 5 cm to 4.4 cm, and aortic valve opening time decreased from
230 ms to 100 ms, with both parameters consistent with normal pump function.
We were unable to obtain good Doppler flow across the mitral valve in diastole to
measure E wave deceleration time. Pump parameters were checked every two to
three weeks with no evidence of major power spikes. A computed tomography
angiogram (CTA) showed no evidence of thrombus formation in the inflow or
outflow cannula. Eight months after device placement and continued LDH
elevation, the patient presented with dark cola-colored urine and LDH was 3360
IU/L. She was experiencing shortness of breath and fatigue not different from her
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symptoms before LVAD placement. The HeartMate II impeller pump was
removed and a HeartWare centrifugal pump was implanted. There was evidence
of pannus formation on the inflow cannula of the HeartMate pump (figure 1).

Figure 1. Intraoperative direct view illustrating pannus formation at LVAD inflow
cannula

The device was sent to Thoratec for analysis who confirmed that a thrombus
aged about 5 days was present. The pannus around the inflow cannula likely
existed for several months, limiting the flow and created low-grade hemolysis
(evident as continued LDH elevation). This low flow state stimulated thrombus
formation triggering gross hemolysis. Lactate dehydrogenase returned to normal
level after LVAD exchange. Figure 2 illustrates the longitudinal LDH values from
the onset of LVAD implantation till its replacement.
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Figure 2. Longitudinal values of lactate dehydrogenase after HeartMate II
placement from device implantation till explant

Discussion
A low level of hemolysis is common in all extracorporeal circuits with a rotatory
pump. Clinically significant hemolysis is one of the feared complications that is
increasingly recognized after LVAD support and is associated with increased
mortality. Ravichandran et al. [7] compared patients with Heartmate II with and
without hemolysis and found that survival in the hemolysis group was markedly
decreased at one year (38.9% vs. 89.3% in those with and without hemolysis,
respectively, p < 0.001). Hemolysis is suspected when a patient develops new
onset anemia in absence of a bleeding source and manifest with dark colacolored urine, elevated plasma free hemoglobin (PFHb), hyperbilirubinemia with
undetectable haptoglobin and elevated LDH [8]. Shah et al. found that an LDH >
600 IU/L for HeartMate II is a superior marker of hemolysis [9] compared with a
PFHb > 40 mg/dl which has been used to define significant hemolysis in the
INTERMACS registry [10]. Other features of hemolysis –as a result of pump
malfunction- include a new palpable pulse, the development of heart failure
symptoms, increased pump power, new opening of the aortic valve and
worsening of mitral regurgitation on echocardiography [11].
The most concerning cause of hemolysis in LVAD patients is pump thrombosis
which should prompt pump replacement or cardiac transplantation to reduce
mortality [5]. Other treatment options include thrombolytic therapy which has a
54.3 % success rate and glycoprotein IIb/IIIa antagonist which has a 39.3 %
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success rate compared with 75.5 % success rate with pump exchange [8]. In the
study by Ravichandran et al., all patients with evidence of hemolysis had partial
to complete pump thrombosis at explant and they concluded that hemolysis likely
serves as a marker of pump thrombosis [7]. Other less common causes of
hemolysis include cannulae/device malpositioning or migration and kinking or
pannus formation on the inflow or outflow cannula. There is little data in the
literature on hemolysis due to pannus formation on the inflow cannula of
HeartMate II. Pannus is an avascular mass of fibrous tissue and its pathogenesis
is not fully understood [12]. Comparison between pannus and thrombus
formation was better studied with prosthetic heart valves. Unlike in thrombus
formation, suboptimal anticoagulation did not appear to be a risk factor for
pannus development; in addition, a longer period is required for pannus
formation, usually 6 months or longer [13]. However, a shorter time interval for
pannus formation has also been reported [14]. In the presented case, pannus
formation likely occurred in the early postoperative period as evident by elevation
of LDH within 2 weeks after LVAD implantation and was responsible for
persistent LDH elevation for 8 months. The onset of clinically manifest hemolysis
occurred with the development of LVAD thrombus due to the continued low flow
state which prompted pump exchange.
In the presented case, preoperative imaging failed to delineate a cause for the
continued LDH elevation. The capacity of echocardiography to evaluate the
inflow and outflow cannula is limited by acoustic window/shadowing and cannula
artifact. Uriel et al. demonstrated that their “ramp” test protocol reliably detected
LVAD thrombosis and malfunction through attenuated reduction in LV
dimensions and increased power detected by the LVAD console with increasing
LVAD pump speed [15]. Estep et al. showed that the best diagnostic parameters
included changes in the LV end-diastolic diameter (<0.6 cm), aortic valve
opening time (<80 msec), and deceleration time of mitral inflow (<70 msec) from
lowest to highest pump speed [16]. Although CTA is an important tool to
delineate the anatomy of the inflow cannula within the left ventricle, the
extracardiac portion cannot be assessed with imaging and intraoperative
inspection is needed. Moreover, it is unable to detect thrombus within the LVAD
pump itself. Identifying the cause of hemolysis using echocardiography, CTA, or
cardiac catheterization may not be definitive and occasionally intraoperative
examination with extensive dissection to visualize the entire system is
mandatory. Mechanical pump or inflow graft failure is therefore a diagnosis of
exclusion and has been identified as the “black box” area that cannot be
examined with preoperative imaging [17]. The presented case highlights one of
the rare causes of chronic hemolysis after LVAD placement which is inflow
cannula pannus formation.

.
The VAD Journal: http://dx.doi.org/10.13023/VAD.2015.12

Page 5 of 7

The VAD Journal: The journal of mechanical assisted circulation and heart failure

References
1. Kirklin JK, Naftel DC, Kormos RL, et al. Fifth INTERMACS annual report: risk
factor analysis from more than 6,000 mechanical circulatory support patients. J
Heart Lung Transplant 2013;32:141-56.
2. John R, Kamdar F, Liao K, Colvin-Adams M, Boyle A, Joyce L. Improved
survival and decreasing incidence of adverse events with the HeartMate II left
ventricular assist device as bridge-to-transplant therapy. Ann Thorac Surg. 2008
Oct;86(4):1227-34; discussion 1234-5.
3. Maciver J, Ross HJ. Quality of life and left ventricular assist device support.
Circulation. 2012 Aug 14;126(7):866-74.
4. INTERMACS. Quarterly Statistical Report, 2013 4th Quarter. Available from:
URL:
http://www.uab.edu/medicine/intermacs/images/Federal_Quarterly_Report/Feder
al_Partners_Report_2014_Q1.pdf . Accessed 1/9/2015.
5. Starling RC, Moazami N, Silvestry SC, Ewald G, Rogers JG, Milano CA, Rame
JE, Acker MA, Blackstone EH, Ehrlinger J, Thuita L, Mountis MM, Soltesz
EG,Lytle BW, Smedira NG.
Unexpected abrupt increase in left ventricular assist device thrombosis. N Engl J
Med. 2014 Jan 2;370(1):33-40.
6. Cowger JA, Romano MA, Shah P, Shah N, Mehta V, Haft JW, Aaronson
KD, Pagani FD.
Hemolysis: a harbinger of adverse outcome after left ventricular assist
device implant. J Heart Lung Transplant. 2014 Jan;33(1):35-43.
7. Ravichandran AK, Parker J, Novak E, Joseph SM, Schilling JD, Ewald
GA, Silvestry S. Hemolysis in left ventricular assist device: a retrospective
analysis of outcomes. J Heart Lung Transplant. 2014 Jan;33(1):44-50.
8. Guglin, Maya and Miller, Leslie W. (2014) "Left Ventricular Assist Device as
Destination Therapy," The VAD Journal: Vol. 1, Article 2.
9. Shah P, Mehta VM, Cowger JA, Aaronson KD, Pagani FD: Diagnosis of
hemolysis and device thrombosis with lactate dehydrogenase during left
ventricular assist device support. The Journal of heart and lung transplantation :
the official publication of the International Society for Heart Transplantation
2014;33:102-4.
10. Interagency Registry for Mechanically Assisted Circulatory Support
(INTERMACS) Official Website. Available at: http://www.intermacs.org.
11. Paluszkiewicz L, Gursoy D, Spiliopoulos S, et al.: HeartMate II ventricular
assist device thrombosis-an echocardiographic approach to diagnosis: can
Doppler evaluation of flow be useful? J Am Soc Echocardiogr 2011;24:350 e1-4.
12. Aoyagi S, Nishimi M, Tayama E, Fukunaga S, Hayashida N, Akashi
H, Kawara T. Obstruction of St Jude medical valves in the aortic position: a
consideration for pathogenic mechanism of prosthetic valve obstruction.
Cardiovasc Surg. 2002 Aug;10(4):339-44.
The VAD Journal: http://dx.doi.org/10.13023/VAD.2015.12

Page 6 of 7

The VAD Journal: The journal of mechanical assisted circulation and heart failure

13. Barbetseas J, Nagueh SF, Pitsavos C, Toutouzas PK, Quiñones MA, Zoghbi
WA. Differentiating thrombus from pannus formation in obstructed mechanical
prosthetic valves: an evaluation of clinical, transthoracic and transesophageal
echocardiographic parameters. J Am Coll Cardiol. 1998 Nov;32(5):1410-7.
14. Cleveland JC, Lebenson IM, Dague JR. Early postoperative development of
aortic regurgitation related to pannus ingrowth causing incomplete disc seating of
a Björk-Shiley prosthesis. Ann Thorac Surg. 1982 May;33(5):496-8.
15. Uriel N., Morrison K.A., Garan A.R., et al: Development of a novel
echocardiography ramp test for speed optimization and diagnosis of device
thrombosis in continuous-flow left ventricular assist devices: the Columbia ramp
study. J Am Coll Cardiol 2012; 60:1764-1775
16. Estep JD, Vivo RP, Cordero-Reyes AM et. al. A simplified echocardiographic
technique for detecting continuous-flow left ventricular assist device malfunction
due to pump thrombosis. J Heart Lung Transplant. 2014 Jun;33(6):575-86.
17. Tchantchaleishvili V, Sagebin F, Ross RE, Hallinan W, Schwarz KQ, Massey
HT. Evaluation and treatment of pump thrombosis and hemolysis. Ann
Cardiothorac Surg. 2014 Sep;3(5):490-5.

The VAD Journal: http://dx.doi.org/10.13023/VAD.2015.12

Page 7 of 7

